
|Videos|July 14, 2015
What the DAPT Trial Means for Pharmacists
Advertisement
Episodes in this series

Advertisement
Related to this article

Treated patients also had fewer post-acute hospitalizations and deaths, but individuals without risk factors saw no benefit.

In a Korean cohort of 1861 patients with nondialysis CKD, intake below 0.6 g/kg/d was linked to more kidney failure and higher all-cause mortality.

Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with the rare airway disease.

Caitlin McClain, a nurse and Clostridioides difficile infection (CDI) survivor, says pharmacists are well placed to help patients tell routine antibiotic adverse effects apart from CDI, which could lead to earlier diagnosis.

A disease-modifying therapy for stage 3 T1D, a second once-weekly insulin, and automated insulin delivery for T2D mark a busy year in diabetes care.

Before lung cancer therapy begins, diagnostic findings and treatment readiness shape care, creating opportunities for pharmacists to help patients start safely.

October’s pain management coverage examined postoperative suzetrigine, pharmacist follow-up for cancer-related neuropathic pain, constipation prevention, and counseling patients concerned about prescribed opioids.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Diabetes Awareness Month Opens Amid New T1D, T2D Approvals
2
Very Low Protein Intake Tied to Higher Kidney Failure Risk in CKD
3
FDA Grants Accelerated Approval to First Plasmid DNA-Based Immunotherapy for Recurrent Respiratory Papillomatosis
4
Kidney Week 2026: Pharmacists' Growing Role in Kidney Care
5






